Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg

Glenmark Pharmaceuticals Ltd. (Glenmark), a research‐led, integrated, global pharmaceutical company hasreceived final approval by the United States Food & Drug Administration (U.S. FDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza®1 Tablets, 2.5 mg and 5 mg, of AstraZeneca AB. Glenmark's Saxagliptin Tablets, 2.5 mg and 5 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

According to IQVIA™ sales data for the 12‐month period ending June 2023, the Onglyza® Tablets, 2.5 mg and 5 mg market2 achieved annual sales of approximately $100.7 million*.

Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace and 49 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 788.20 as compared to the previous close of Rs. 798.50. The total number of shares traded during the day was 52952 in over 2476 trades.

The stock hit an intraday high of Rs. 824.65 and intraday low of 786.20. The net turnover during the day was Rs. 42398708.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 FinalApproval USFDA SazagliptinTablets